Alpha 2.0
Login Register
» Authors » Hubert Schefer

Hubert Schefer

Explore the profile of Hubert Schefer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 101
Followers 0
Related Specialties
Oncology
Radiology
Endocrinology
Top 10 Co-Authors
Daniel C Betticher
Martin F Fey
Mario Bargetzi
Simon Peter Gampenrieder
Arne Fischmann
Sebastian Kos
Roger Von Moos
Christian Riklin
Urs E Studer
Evanthia Karamitopoulou-Diamantis
Published In
J Clin Oncol
Support Care Cancer
Front Endocrinol (Lausanne)
J Urol
Onkologie
Affiliations
Soon will be listed here.
Recent Articles
1.
Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH
Menzi S, Jaramillo S, Pfister S, Schefer H, Jehle A
Front Endocrinol (Lausanne) . 2024 May; 15:1382066. PMID: 38803472
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is frequent in lung cancer patients. Here, we report a case with persistent hyponatremia, which suggested malignant SIADH and facilitated an early...
2.
"I was seen by a radiologist, but unfortunately I can't remember the name and I still have questions. What should I do?" Radiologists should give thoughts to improve service professionalism and patient esteem
Gutzeit A, Fischmann A, Forstner R, Goette R, Herzog B, Kurtz C, et al.
Cancer Imaging . 2020 Feb; 20(1):18. PMID: 32054513
Background: The aim of the study is to investigate how well patients remember the radiologist's name after a radiological examination, and whether giving the patient a business card improves the...
3.
Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer
Gautschi O, Schefer H, Riklin C, Strobel K, Diebold J
Onkologie . 2013 Jun; 36(6):342-7. PMID: 23774148
Background: Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK), is approved since 2012 in Switzerland for use in ALK-rearranged advanced pretreated non-small cell lung cancer (NSCLC). Patients And Methods:...
4.
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
Betticher D, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Muller A, et al.
Support Care Cancer . 2013 May; 21(9):2565-73. PMID: 23636645
Purpose: Chemotherapy-induced alopecia is very distressing for a patient and may have an impact on treatment decisions. On docetaxel-based therapy, alopecia occurs in a substantial proportion of patients. We aimed...
5.
Microangiopathic haemolytic anaemia in a patient with metastatic breast cancer
Himmelmann A, Schefer H
Br J Haematol . 2009 Feb; 146(3):231. PMID: 19183189
No abstract available.
6.
Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis
Westermann D, Schefer H, Thalmann G, Karamitopoulou-Diamantis E, Fey M, Studer U
J Urol . 2007 Nov; 179(1):163-6. PMID: 18001800
Purpose: We evaluated the long-term outcome after 1 cycle of adjuvant modified bleomycin, etoposide and cisplatin chemotherapy in patients who underwent orchiectomy for high risk clinical stage I nonseminomatous germ...
7.
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Hsu Schmitz S, Cogliatti S, Bertoni F, Waltzer U, Fey M, et al.
J Clin Oncol . 2004 Dec; 23(4):705-11. PMID: 15598978
Purpose: To evaluate the effect of single-agent rituximab given at the standard or a prolonged schedule in patients with newly diagnosed, or refractory or relapsed mantle cell lymphoma (MCL). Patients...